Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.39 billion
Profitability
Miscellaneous
Employees24,000
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $0.61 EPS for the quarter, beating the Zacks' consensus estimate of $0.59 by $0.02. The company earned $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. Syneos Health's revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of $3.08-3.26 for the period, compared to the Thomson Reuters consensus estimate of $3.11. The company issued revenue guidance of $4.64-4.75 billion, compared to the consensus revenue estimate of $4.68 billion.
What price target have analysts set for SYNH?
9 brokerages have issued twelve-month price targets for Syneos Health's shares. Their forecasts range from $48.00 to $68.00. On average, they anticipate Syneos Health's share price to reach $59.1429 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
Media coverage about SYNH stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Syneos Health.
Are investors shorting Syneos Health?
Syneos Health saw a decrease in short interest in the month of August. As of August 15th, there was short interest totalling 5,930,300 shares, a decrease of 5.3% from the July 15th total of 6,263,000 shares. Based on an average daily volume of 502,300 shares, the short-interest ratio is presently 11.8 days. Approximately 9.7% of the shares of the stock are sold short. View Syneos Health's Current Options Chain.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Syneos Health own?
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair Macdonald, CEO & Director (Age 49)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
- Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
- Mr. Michael Adam Bell, Consultant (Age 63)
- Mr. Robert Parks, Exec. VP & Chief Accounting Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Thomas H Lee Partners LP (18.55%), BlackRock Inc. (8.25%), BlackRock Inc. (8.25%), Vanguard Group Inc. (7.39%), Mackenzie Financial Corp (2.68%) and Viking Global Investors LP (1.74%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which institutional investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Price T Rowe Associates Inc. MD, Pictet Asset Management Ltd., Pictet Asset Management Ltd., D. E. Shaw & Co. Inc., Invesco Ltd., Mackenzie Financial Corp and Bank of America Corp DE. View Insider Buying and Selling for Syneos Health.
Which institutional investors are buying Syneos Health stock?
SYNH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Victory Capital Management Inc., Boston Partners, Vanguard Group Inc., Point72 Asset Management L.P., Magnetar Financial LLC, Rothschild & Co. Asset Management US Inc. and JPMorgan Chase & Co.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $54.92.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $5.68 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
